One of the first validated tools to predict before treatment if a patient will have a favorable biochemical response in patients with metastatic hormone-sensitive prostate cancer.

By identifying patients who are unlikely to achieve an early favorable prostate specific antigen (PSA) response, clinicians may be able to intervene sooner, consider treatment intensification, or prioritize enrollment in clinical trials.

Results published in Nature Communications.

The findings, published Jan. 8 in JAMA Oncology, support the potential benefits of screening patients for CHIP before they undergo cancer treatment so they can be more closely monitored for heart complications. CHIP is a condition, not a disease, characterized by age-related variants in blood stem cells, and it is typically asymptomatic.

The Mount Sinai Tisch Cancer Center (TCC) has launched a new artificial intelligence (AI) platform to help connect more cancer patients across the Mount Sinai Health System to life-saving clinical trials. The platform, which was created by the AI company Triomics, is called PRISM, and is powered by Triomics’ OncoLLM, a large language model-based pipeline built especially for cancer care. As an early adopter of this new technology, Mount Sinai becomes the first National Cancer Institute (NCI)-designated Comprehensive Cancer Center in New York City to deploy this oncology-specific AI tool for systemwide clinical trial matching.

Caregivers of individuals diagnosed with acute leukemia face a difficult balancing act: meeting the urgent demands of cancer care while managing their daily responsibilities. A new qualitative study highlights the profound toll of this dual role and underscores the need for caregiver support as an essential part of cancer care.

Researchers have developed a method to help cancer immunotherapies reach otherwise “invisible” tumors by helping guide therapies to their appropriate targets. This could be particularly useful for very difficult-to-treat tumors like neuroblastoma.